Skyrizi® (risankizumab-rzaa)

Skyrizi (risankizumab‑rzaa) is covered for FDA‑approved adult indications—moderate to severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active Crohn’s disease—when used per label. Coverage requires age ≥18 where specified, specialty prescriber/consult (dermatologist for psoriasis; rheumatologist or dermatologist for PsA; gastroenterologist for Crohn’s), documentation of required prior therapy trials or contraindications (e.g., a 3‑month trial/intolerance to a biologic or traditional systemic agent for psoriasis; prior systemic therapy or corticosteroid use or qualifying surgical/fistula history for Crohn’s), Crohn’s IV induction within 3 months of subcutaneous initiation, adherence to dosing/authorization timelines, and objective documentation of clinical benefit for reauthorization (90 days for psoriasis; 6 months for PsA and Crohn’s).

"Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy."